Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax.

ABSTRACT:

SUBMITTER: Rausch J 

PROVIDER: S-EPMC10543165 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature